Healthcare professionals' perceptions and management of obesity & knowledge of glucagon, GLP‐1, GIP receptor agonists, and dual agonists

Documenti analoghi

• Orforglipron, a novel non‐peptide oral daily glucagon‐like peptide‐1 receptor agonist as an anti‐obesity medicine: A systematic review and meta‐analysis
  di: Deep Dutta, et al.
  Pubblicazione: (2024)
• Digital engagement enhances dual GIP / GLP ‐1 receptor agonist and GLP ‐1 receptor agonist efficacy: A retrospective cohort analysis of a digital weight loss service on outcomes and safety
  di: Hans Johnson, et al.
  Pubblicazione: (2025)
• GLP ‐1 receptor agonists and cardiovascular events in metabolically healthy or unhealthy obesity
  di: Tommaso Bucci, et al.
  Pubblicazione: (2025)
• Patient perceptions of success in obesity treatment: An IMI2 SOPHIA study
  di: E. Farrell, et al.
  Pubblicazione: (2024)
• Potential role of glucagon like peptide (GLP)‐1 receptor agonist to reduce risk of colorectal cancer?
  di: Iskandar Idris
  Pubblicazione: (2024)